Literature DB >> 18324421

Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome.

Viktória Sümegi1, Ibolya Haszon, Csaba Bereczki, Ferenc Papp, Sándor Túri.   

Abstract

A retrospective study was made on 37 children with idiopathic nephrotic syndrome (INS). At the beginning, all patients were steroid sensitive but received more than one steroid course (median 4). Following several relapses, they became steroid dependent or steroid resistant. Group 1 consisted of 22 children [3 focal segmental glomerulosclerosis (FSGS), 19 minimal-change NS (MCNS)] who received cyclophosphamide (CP) orally for 2.5 +/- 0.5 months. Group 2 consisted of 15 children (7 FSGS, 8 MCNS) who received cyclosporine-A (CSA) for 28 +/- 15 months. The level of proteinuria decreased significantly and remained low during the follow-up. The relapse-free period was significantly longer in the CP group (CP 30 +/- 21.5; CSA 26.2 +/- 18 months, p < 0.001). The relapse rate decreased significantly in both groups and remained in this lower level during the follow-up (from 3.4 +/- 2.8 to 0.1 +/- 0.2/year in group 1, and from 3.7 +/- 3.1 to 0.6 +/- 0.8/year in group 2). At the end of the 5-year follow-up, 20/22 patients (90.9%) and 10/15 patients (66.6%) were in remission in groups 1 and 2 respectively, with or without treatment (p < 0.05). In the long term, both CP and CSA is effective second-line therapy following steroid monotherapy in INS patients, but the relapse rate was lower and the relapse free period was significantly longer in the CP-treated group.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324421     DOI: 10.1007/s00467-008-0771-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  37 in total

1.  Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children.

Authors:  M Abramowicz; H L Barnett; C M Edelmann; I Greifer; O Kobayashi; G C Arneil; B A Barron; G Gordillo-P; N Hallman; H A Tiddens
Journal:  Lancet       Date:  1970-05-09       Impact factor: 79.321

2.  Therapeutic and toxic effects observed with different dosage programs of cyclophosphamide in treatment of steroid-responsive but frequently relapsing nephrotic syndrome.

Authors:  W W McCrory; M Shibuya; W H Lu; J E Lewy
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

3.  Cyclosporin and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy.

Authors:  R Zietse; F H Derkx; M A Schalekamp; W Weimar
Journal:  Contrib Nephrol       Date:  1995       Impact factor: 1.580

Review 4.  Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians.

Authors: 
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

5.  Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose.

Authors:  A S Chishti; J M Sorof; E D Brewer; A S Kale
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

6.  Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome.

Authors:  K Hamahira; K Iijima; R Tanaka; H Nakamura; N Yoshikawa
Journal:  Pediatr Nephrol       Date:  2001-09       Impact factor: 3.714

7.  Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors: 
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

8.  National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification.

Authors:  Ronald J Hogg; Susan Furth; Kevin V Lemley; Ronald Portman; George J Schwartz; Josef Coresh; Ethan Balk; Joseph Lau; Adeera Levin; Annamaria T Kausz; Garabed Eknoyan; Andrew S Levey
Journal:  Pediatrics       Date:  2003-06       Impact factor: 7.124

9.  Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology.

Authors:  P Niaudet
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

Review 10.  Nephrotic syndrome in childhood.

Authors:  Allison A Eddy; Jordan M Symons
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321

View more
  14 in total

Review 1.  New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.

Authors:  Michael van Husen; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2011-01-13       Impact factor: 3.714

2.  Oral cyclophosphamide therapy in 100 children with steroid-sensitive nephrotic syndrome: experience from a developing country.

Authors:  Jasjeet Sandhu; Deepak Bhat; Gurdeep Singh Dhooria; Puneet A Pooni; Siddharth Bhargava; Shruti Kakkar; Karambir S Gill
Journal:  Pediatr Nephrol       Date:  2021-03-31       Impact factor: 3.714

Review 3.  Podocyte-actin dynamics in health and disease.

Authors:  Luca Perico; Sara Conti; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

4.  Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis.

Authors:  Yuko Hamasaki; Norishige Yoshikawa; Hitoshi Nakazato; Satoshi Sasaki; Kazumoto Iijima; Koichi Nakanishi; Takeshi Matsuyama; Kenji Ishikura; Shuichi Ito; Tetsuji Kaneko; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2013-01-13       Impact factor: 3.714

5.  Mycophenolate mofetil (MMF) treatment efficacy in children with primary and secondary glomerulonephritis.

Authors:  Danuta Ostalska-Nowicka; Agnieszka Malinska; Magdalena Silska; Bartlomiej Perek; Jacek Zachwieja; Michal Nowicki
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

6.  Recurrent focal segmental glomerulosclerosis: a discrete clinical entity.

Authors:  Elena Torban; Martin Bitzan; Paul Goodyer
Journal:  Int J Nephrol       Date:  2012-01-11

7.  Macrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis.

Authors:  Rafał Zwiech
Journal:  BMC Immunol       Date:  2015-08-14       Impact factor: 3.615

8.  Pharmacokinetics of cyclosporin--a microemulsion in children with idiopathic nephrotic syndrome.

Authors:  Luciana dos Santos Henriques; Fabíola de Marcos Matos; Maria Helena Vaisbich
Journal:  Clinics (Sao Paulo)       Date:  2012-10       Impact factor: 2.365

9.  S-Fas urinary excretion helps to predict the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis.

Authors:  Rafał Zwiech
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

10.  Some optimal culture conditions for production of cyclosporin a by Fusarium roseum.

Authors:  Ahmed A Ismaiel; A El-Sayed; Asmaa A Mahmoud
Journal:  Braz J Microbiol       Date:  2010-12-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.